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Hepatitis B virus (HBV) X gene is known to exhibit a transcriptional activation function and is considered to play a major
role in hepatocarcinogenesis. We determined a 20-bp promoter element for the HBV X gene transcription and found a
binding protein to this promoter element, designated as an X-PBP. We then examined the effects of HBV X protein and p53
tumor suppressor gene product on X gene transcription from the 20-bp promoter element using the transient expression
technique. Activity of the X gene promoter was stimulated by X protein expression, but, in contrast, was repressed by
transfected normal p53 gene. On the other hand, mutant p53 gene product exhibited no repression. Moreover, the p53
repression of X gene transcription was canceled by X protein coexpression. Thus, the effects of X protein and normal p53
product appear to be mutually antagonistic in the regulation of X gene expression. However, mutated promoter elements
which failed to bind to X-PBP still responded to X protein or p53, indicating that the process of X transactivation or p53
respression may be independent of X-PBP binding to the promoter element. Our data suggest that X protein could disrupt
function of normal p53 protein in X gene-transfected cells. q 1996 Academic Press, Inc.
INTRODUCTION Twu et al., 1989a), but not for SV40 enhancer in CV-1
cells (Seto et al., 1990). When focused on one particular
Hepatitis B virus (HBV) is closely related not only to gene, the efficacy of transactivation was found to be
acute or chronic hepatitis, but also to the development dependent on the cell line that was used in the experi-
of hepatocellular carcinoma (HCC) (for review, see Tiol- ment (Seto et al., 1989). Thus, the XRE should be deter-
lais et al., 1985; Ganem and Varmus, 1987). One of the mined, respectively, for each cell line.
HBV genes, X, encodes a basic protein of 154 amino Although the reported observations and the proposed
acids and has been implicated in the carcinogenicity of mechanisms were not, in fact, always consistent, it appears
this virus as a major causative factor because of its ability that X protein exerts its transcriptional activation function
to induce the transformation of rodent cells (Shirakata et via protein–protein interaction with cellular factors. Several
al., 1989; Hohne et al., 1990; Rakotomahanina et al., 1994) reports have indicated that X protein activated some signal
and to induce HCC in transgenic mice (Kim et al., 1991). transduction factors (Kekule et al., 1993; Cross et al., 1993;
The X protein is known to exhibit a transcriptional activa-
Natoli et al., 1994a; Benn and Schneider, 1994) or DNA
tion function for many viral and cellular genes without
binding of some transcription factors (Natoli et al., 1994b).
binding to DNA (Spandau and Lee, 1988; for review, Ros-
On the other hand, X protein directly interacted with hepatic
sner, 1992).
serine proteases, tryptase TL2, and tryptase TL1 (a member
As to the responsive element for X protein (X-respon-
of proteasome), as an inhibitor (Takada and Koike, 1990a;
sive element, XRE), AP-1 and AP-2 binding sequences
Takada et al., 1994a). This indicates the possibility that X
were previously found in SV40 enhancer (Seto et al.,
protein activates the signal transduction pathway as well
1990), NFkB-like sequence in the HIV LTR (Siddiqui et
as transcription by inhibiting the activity of serine proteasesal., 1989; Twu et al., 1989a,b), and the 26-bp XRE in HBV
that might be involved in proteolytic cleavage of transcrip-enhancer I (Faktor et al., 1990). Accordingly, the X protein
tion factors or signal transduction factors. However, wewas expected to transactivate a certain gene through a
could not exclude the possibility that these observationsdifferent XRE in each cell line; for example, the AP-2
were indirect outcomes of the transcriptional activation ofbinding sequence responded to X protein in CV-1 cells
several genes by X protein, because these serine proteases(Seto et al., 1990), but not in HepG2 cells (Twu et al.,
are localized in the cytoplasm (Kido et al., 1990; Tanaka et1989a), and a kB-like sequence was reported to be the
al., 1992), and X protein is detected mainly in the cytoplasmXRE for the HIV LTR in HepG2 cells (Siddiqui et al., 1989;
(Siddiqui et al., 1987; Benn and Schneider, 1994).
As it is increasingly important to understand how X
gene expression is regulated, we previously analyzed X1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 81-3-5394-3902. gene expression with a particular focus on the promoter-
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containing region and found that the 58-bp region, 130 activity was counteracted by the presence of X protein.
From the viewpoint of functional disruption of normal p53bp upstream from the first ATG codon of X ORF, has
promoter activity (Nakamura and Koike, 1992). In addi- in the nucleus by X protein coexpression, the transactiva-
tion mechanism in X gene-transfected cells is discussed.tion, a ubiquitous protein (complex), designated as an X-
PBP (X promoter binding protein), was shown to bind this
58-bp DNA (Nakamura and Koike, 1992; Yaginuma et al., MATERIALS AND METHODS
1993). In this study, deletion analyses were performed
Plasmid DNAson this 58-bp region and a small 20-bp region of promoter
activity of the X gene was determined. We then ques- pX58pCAT, pX58pM1CAT, and pX58pM2CAT were pre-
tioned whether X protein regulates the X gene promoter. viously described by Nakamura and Koike (1992). pX58pM4
The promoter activity of the 20-bp DNA was activated by  pX58pM7CAT, pX58pM7mCAT (SphI site was mutated
X protein expression, but we were not able to observe the from GCATGC to TTTTTT), pXMP1CAT pXMP3CAT, and
direct involvement of X-PBP in the process of promoter pXMP2mCAT (the SphI site was mutated from GCATGC to
activation by X protein. GACTGC) were constructed by ligation of each chemically
The p53 tumor suppressor gene product is mainly lo- synthesized double-stranded mutant X promoter DNA into
cated in the nucleus and has pleiotropic functions, in- the HindIII site of pSV00CAT (Araki et al., 1988). pHBVX-1
cluding the control of genomic instability (Harris and (Kobayashi and Koike, 1984; Yaginuma et al., 1987), which
Hollstein, 1993). The p53 protein controls gene transcrip- was constructed by insertion of a 0.87-kb StuI/BglII (nt
tion by binding to the specific DNA sequence and to 872–1858) fragment of HBV DNA containing the X gene
other cellular factors (such as Mdm-2, TBP, and WT1) and expression unit into the BamHI site of pBR322, was used
may be involved in DNA replication and repair processes as the X gene expression plasmid. Expression plasmids
(Seto et al., 1992; Kastan et al., 1992; Oliner et al., 1992; pEFX and pEFX-DRsaI were also used as the wild-type or
Momand et al., 1992; Dutta et al., 1993). Mutations on mutant X gene expression, where the wild-type or DRsaI
p53 were found in a wide variety of human cancers (Har- (Arii et al., 1992) mutant X gene ORF was driven under the
ris and Hollstein, 1993; Hollstein et al., 1991). p53 mis- control of the EF1a (elongation factor 1a) gene promoter
sense mutants not only lose normal function, but often (Kim et al., 1990). p53 expression plasmids pCMVp53(nor-
gain oncogenic properties (Wolf et al., 1984; Dittmer et mal), pCMVOM1, pCMVp53d(346-393), pCMVp53d(302-
al., 1993; Gerwin et al., 1992). In virally transformed cells, 393), pCMVp53d(283-393), and pCMVp53DN were con-
p53 protein complexes with viral oncoproteins, such as structed by inserting the normal or mutant p53 ORFs into
the SV40 large tumor antigen(T) (Lane and Crawford, a CMV vector (CLONTECH). pCMVOM1 is a point mutant
1979; Linzer and Levine, 1979), the adenovirus E1B pro- p53, in which Glu was replaced by Gly (aa 266) (Sakai and
tein (Sarnow et al., 1982), the human papillomavirus E6 Tsuchida, 1992). pCMVp53d(346-393), pCMVp53d(302-393),
protein (Dyson et al., 1989), and the Epstein–Barr virus- and pCMVp53d(283-393) are mutant p53s which have lost
encoded nuclear antigen EBNA-5 (Subler et al., 1992). the C-terminal region from aa 346, 302, and 283, respec-
These protein–protein interactions can inactivate p53 tively, to the C-terminus (Tsutsumi-Ishii et al., 1995).
functions, e.g., sequence-specific DNA binding and gene pCMVp53DN is an N-terminal deletion (aa 1–159) mutant.
transactivation and, thus, are important to viral oncoge-
nicity. On the basis of the general acceptance that the Cell line, DNA transfection, CAT activity assay, and
tumor suppressor gene p53 regulates transcriptional ini- Northern blot hybridization
tiation of a variety of viral and cellular genes by direct
HepG2 is a hepatoblastoma cell line containing normalinteraction with the basal transcription factors (Zambetti
p53. Saos-2 (ATCC HTB85), which lacks endogenous p53et al., 1992; Kern et al., 1991; Farmer et al., 1992; Seto
(Masuda et al., 1987), is a human osteosarcoma cell line.et al., 1992; Ragimov et al., 1993), we questioned whether
HuH-7 is a hepatocellular carcinoma cell line which hasthe p53 gene product directly regulates the X gene pro-
mutant p53 (Bressac et al., 1990). DNA transfection, CATmoter. As we preliminarily reported that p53 repressed
activity assay, and Northern blot hybridization were car-X gene transcription from the 58-bp promoter-containing
ried out as described (Takada and Koike, 1990b). ToDNA using the CAT assay system (Takada et al., 1994b),
quantify the reaction products of the CAT assay, radioac-in the present study, we examined the promoter activity
tive spots were cut out from the silica gel plate andof the 20-bp sequence in the presence of transfected
their radioactivity was measured with a liquid scintillationnormal p53 gene. As a result, the 20-bp promoter activity
counter. Relative activity (RA) was calculated and de-was clearly repressed by transfected normal p53 gene,
picted in each respective figure.but not by its mutants. In contrast, under similar condi-
tions, the muscle creatine kinase gene promoter was Electrophoretic mobility shift assay
activated (Takada et al., 1994b), consistent with the previ-
ous data (Weintraub et al., 1991; Zambetti et al., 1992). Nuclear extracts were prepared according to the
method of Dignam et al. (1983). Binding reactions wereInterestingly, when normal p53 gene was coexpressed
with X gene, the repressive effect of p53 on the promoter carried out in 10 ml of the buffer containing 10 mM Tris–
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HCl (pH 7.5), 50 mM NaCl, 1 mM DTT, 1 mM EDTA, 5%
glycerol, 200 mg/ml poly(dA-dT)-poly(dA-dT) (Pharmacia),
300 mg/ml protein concentration of nuclear extract, and
2 1 104 cpm of 32P-labeled probe DNA for 20–30 min
at room temperature, unless otherwise indicated. One
microliter of dye solution [10 mM Tris–HCl (pH7.5), 50%
glycerol, 0.4% bromophenol blue, 0.4% xylene cyanol]
was added to each sample, before it was loaded onto a
4% acrylamide gel containing 6.7 mM Tris–HCl (pH7.5),
1 mM EDTA, 3.3 mM NaoAc, and 2.5% glycerol and then
run in 6.7 mM Tris–HCl (pH7.5), 3.3 mM NaoAc, and 4
mM EDTA. In the supershift experiments, 300 ng of anti-
p53 antibody PAb421, PAb1801 (Oncogene Science), or
anti-SV40 T-Ag antibody (Oncogene Science) was in-
FIG. 1. Determination of a small essential region for the HBV X genecluded in the binding reaction.
promoter. The upstream region of the X gene is shown schematically
at the top. Enh I means the enhancer I of HBV. St, Ba, Sp, and Mb
RESULTS indicate the cleavage sites of StuI, Bal I, SphI, and MboI, respectively.
The Bal I/MboI fragment is the 58-bp DNA fragment which contains the
Determination of a small essential region for the X gene promoter (Nakamura and Koike, 1992). Various sections of this
promoter activity of HBV X gene 58-bp DNA or their mutants indicated in the figure were chemically
synthesized and connected to pSV00CAT, and their promoter activities
The promoter-containing region of the HBV X gene were measured by CAT activity assay using 2 or 10 mg of each CAT
was previously identified by CAT activity assay as the construct per 10-cm dish. Relative promoter activity of each inserted
DNA is shown to the right. Location of the 20-bp promoter is presented58-bp Bal I/MboI DNA fragment (nt 1085–1142) (Naka-
by the hatched box and its nucleotide sequence is shown below. Inmura and Koike, 1992). This 58-bp DNA fragment has no
the MP2m mutant, the sequence GCATGC at the SphI site in MP2 DNAenhancer activity, but contains the major start site of X
was changed to GACTGC.
mRNA (Nakamura and Koike, 1992; Yaginuma et al.,
1993). It was interesting to determine a small essential
sequence for the promoter activity of X gene, because of pX58pCAT, was tested for its CAT activity.
pX58pM2CAT exhibited about one-eighth (162 versusthe promoter-containing region (58-bp DNA fragment) (nt
1085–1142) possesses none of the typical promoter se- 1250) the CAT activity of pX58pCAT, which corresponded
to 12.5-fold that of pX58pM4CAT (data not shown). Thequences, such as the TATA, GC, and CAAT boxes. As
shown in Fig. 1, various promoter-containing DNAs essential region for the promoter activity could thus be
restricted to the 20-bp MP2 DNA sequence (nt 1102–within the 58-bp DNA fragment were synthesized, intro-
duced into the pSV00CAT plasmid, and analyzed for their 1121), where the major start site of X mRNA was present.
The 20-bp sequence is separated from the NF-1 bindingpromoter activity by CAT activity assay, using HepG2
cells as the host. The promoter activity was found to site (nt 1088–1100) (Kobayashi and Koike, 1984).
We previously demonstrated the interaction of X-PBPreside in the 20-bp MP2 DNA (nt 1102–1121) in the
pXMP2CAT plasmid, whose sequence is shown at the with the promoter region of the X gene by a mobility shift
assay using the 58-bp BalI/MboI DNA fragment as thebottom of Fig. 1. This 20-bp sequence overlaps the X-PBP
protected region (nt 1096–1117), which was detected probe (Nakamura and Koike, 1992). DNaseI footprinting
experiments localized the binding site at the sequence be-as a major shifted band by a mobility shift assay using
sonicated salmon sperm DNA as a nonspecific competi- tween nt 1096 and 1117, which contains an 8-bp palin-
dromic sequence with an SphI cleavage site (nt 1110) attor instead of poly(dI-dC) (Nakamura and Koike, 1992).
Mutation at the SphI site (GCATGC to GACTGC) in the its center. The mutations introduced into this target se-
quence for X-PBP binding remarkably reduce transcription20-bp sequence greatly reduced the promoter activity
(see pXMP2mCAT), indicating that the CA sequence in from the major start site of CAT mRNA using the BalI/MboI
DNA–CAT construct (pX58pCAT) (Nakamura and Koike,the SphI site of 20-bp DNA is essential for the activity.
Truncation or deletion of half of the MP2 DNA resulted 1992). Therefore, the binding of X-PBP was shown to be
essential for the initiation of X gene transcription. Thesein loss of the promoter activity (see pX58pM5CAT and
pXMP3CAT). The exact reason why pX58pM6 CAT exhib- data indicate an important role of X-PBP in the regulation
of X gene expression. To further examine the binding regionited slightly lower activity compared to pX58pM4CAT is
not known, but as a result of a deletion, a negative ele- for X-PBP, a mobility shift assay was performed using vari-
ous X gene promoter-containing DNAs. Results indicatedment at the 3* end region was close to the 20-bp se-
quence and may have had an effect on it. Actually, that M7 DNA, the insert of the pX58pM7CAT plasmid (Fig.
1), had the capacity to bind X-PBP. Competition experimentspX58pM7CAT without the 3* end region exhibited higher
activity. In addition, pX58pM2CAT, containing a mutation against M7 DNA were then carried out with various deletion
mutant DNAs (Fig. 2A). A mobility shift assay was alsoat the SphI site (GCATGC to TTTTTT) in the 58-bp region
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performed using wild-type or mutant DNAs as the probe
(Fig. 2B). The 20-bp MP2 DNA (nt 1102–1121) was found
to be sufficient for the binding of X-PBP, although X-PBP
protected a larger area in the DNaseI footprinting experi-
ments (Nakamura and Koike, 1992; Yaginuma et al., 1993).
The point mutant MP2m (the insert of pXMP2mCAT plas-
mid) showed much reduced X-PBP binding activity (Fig. 2B),
suggesting that the sequence ‘‘CA’’ in the SphI site is in the
recognition site of X-PBP. MP2m DNA also exhibited much
FIG. 3. Transcriptional activation of the X gene promoter by HBV Xreduced promoter activity (Fig. 1). Although the physiologi-
protein. The CAT plasmid containing wild-type or mutant X promotercal function of X-PBP has not yet been fully investigated,
was cotransfected with the X gene expression plasmid (pHBVX-1 indi-the binding activity of X-PBP to normal or mutant promoter cated as /) or the control plasmid (pBR322 indicated as 0) of 10 mg
DNA is well correlated with the promoter activity, consistent per 10-cm dish into HepG2 cells, and then CAT activity was assayed.
with previous observations (Nakamura and Koike, 1992; As the basal activity of the reporter plasmid varied (see Fig. 1), the
amount of the transfected reporter plasmid DNAs was adjusted; 2 mgYaginuma et al., 1993).
for MP2 (pXMP2CAT), M4 (pX58pM4CAT), and M7 (pX58pM7CAT), and
10 mg for MP2m (pXMP2mCAT) and MP3 (pXMP3CAT), in order toActivation of the X gene promoter activity by X
clarify the difference between the basal and activated promoter activi-protein ties. Similar results were obtained when 10 mg of pEFX was used as
the X expression plasmid. Relative activity (RA) for the basal activity ofSince X protein is known to activate transcription of
each reporter plasmid was calculated and is shown at the top.many genes through various DNA elements, it was of
interest to determine whether X protein is able to activate
the X gene promoter. CAT activity assay was performed X-responsive element was present in X gene promoter
using various X gene promoter CAT constructs and the and that X protein was able to activate X gene expression
X gene expression plasmid (pHBVX-1) or the control plas- as long as the promoter activity was detected. When
mid (pBR322). As the basal CAT activity of the reporter Northern blot analysis of the CAT mRNA that was ex-
plasmid varied (see Fig. 1), the amount of each pressed in X gene-transfected or nontransfected cells
transfected reporter plasmid DNA was adjusted (2 mg for was carried out, CAT mRNA was found to have increased
pXMP2CAT, pX58pM4CAT, and pX58pM7CAT and 10 mg in the X-transfected cells as a function of the amount of
for pXMP2mCAT and pXMP3CAT), in order to clearly dis- X gene transfection (data not shown). These data support
tinguish the difference in activity between basal and acti- our indication that activation of the X gene promoter activ-
vated promoters. Interestingly, transcription from the ity by transfected X gene is not merely caused by overex-
small 20-bp DNA (MP2 or MP2m) was clearly activated by pression of X protein in the transient expression system.
X protein, but MP3 was not (Fig. 3). All reporter plasmids, Next, we investigated whether the X-PBP is directly
except pXMP3CAT, were similarly activated by X protein involved in the transactivation function of X protein. A
coexpression in their extent. The data indicated that an mutated X gene promoter (MP2m), to which X-PBP was
weakly bound (Fig. 2B), was analyzed for its response to
X protein. As shown in Fig. 3, the mutant pXMP2mCAT
was still responsive to transactivation by X protein, al-
though the mutant had much weaker promoter activity
(see Fig. 1) than that of the wild-type construct
(pXMP2CAT), indicating that X-PBP was not a direct me-
diator of the X protein function. In addition, pX58pM2CAT
was tested for its response to X protein, since
pX58pM2CAT does not bind X-PBP at all (Nakamura and
Koike, 1992). pX58pM2CAT was transactivated by
transfected pHBVX-1 DNA (data not shown). These ob-
servations suggest that X promoter activation by X pro-
tein is not directly mediated by X-PBP.
FIG. 2. Determination of the essential region for X-PBP binding. (A)
Competition experiment. A mobility shift assay was carried out using Repression of the X gene promoter activity by
32P-M7 DNA (see Fig. 1) as the probe, HepG2 nuclear extract, and 100 transfected p53 gene
ng of the indicated DNAs as the competitors. (B) X-PBP binding to the
promoter DNA. A mobility shift assay was carried out using various It has been reported that the p53 tumor suppressor
32P-labeled promoter DNAs as the probes. Specific activities (cpm/ gene product was directly involved in transcription initia-
pmol) of the probes were M7m, 1.3 1 106; M7, 1.9 1 106; MP2, 1.1 1
tion through the TATA box binding protein (Seto et al.,106; MP2m, 9.6 1 105; and MP3, 9.0 1 105, respectively. Black triangles
1992) and TBP-associated factors (TAFII40 and TAFII60)indicate the positions of the X-PBP band. The M7m DNA was used as
a negative control. (Thut et al., 1995). However, the 58-bp Bal I/MboI DNA
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TABLE 1 Northern blot analysis of X mRNA transcribed from the
expression plasmid pHBVX-1 or pHBV dimer in the p53-Repression of X Gene Transcription by Transfected
transfected or nontransfected cells was further carriedTumor Suppressor Gene p53 and Its Mutant
out, X mRNA was found to have been reduced in the p53
Relative CAT activity gene-transfected cells (Fig. 4B). These data support our
proposal that repression of X gene promoter activity by
Reporter plasmid
transfected normal p53 gene is not caused merely byExpression
overexpression of p53 protein in the transient expressionplasmid pX58pCAT pX58pM1CAT pEtCAT
system, but may reflect regulation of X gene expression
None (vector) 1 1 1 in HBV DNA-infected cells (Takada and Koike, 1990b).
p53 0.1 0.1 16.9 Next, we investigated whether X-PBP is directly in-
p53 mutant DN 1.7 1.8 0.8
volved in the transcriptional repression function of nor-p53 mutant OM1 2.6 2.9 1.7
mal p53 protein. A mutated X gene promoter, MP2m (two-
Note. Saos-2 cells were cotransfected with the indicated plasmids nucleotide substitution at the SphI site), to which X-PBP
and CAT activity was determined relative to that of the controls. The bound weakly (Fig. 2B), was analyzed in terms of its
vector for the expression plasmid contained the CMV promoter. For response to the p53 protein. As shown in Fig. 4C, the
most experiments, the quantity of reporter plasmid containing 58-bp
wild-type X promoter (pXMP2CAT) and the mutant X pro-DNA (pX58pCAT) or its mutant (pX58pM1CAT) was 1 mg per dish, that
moter (pXMP2mCAT) were similarly responsive to p53of the expression plasmid was 1 mg per dish, and the corresponding
vector was used to adjust the amount of total DNA in each experiment. repression in their extent, although X-PBP binding activity
pEtCAT, a CAT construction of the creatine kinase gene promoter as was much weaker in the mutant than in the wild-type
the positive control. DN, amino-terminal deletion (aa 1–159). OM1, (pXMP2CAT), indicating that X-PBP was unlikely to be a
point mutation Gly (aa 226) r Glu.
direct mediator of the p53 function. pX58pM2CAT (Naka-
mura and Koike, 1992) was also tested for its response
to p53 repression, since pX58pM2CAT does not bind X-has neither a p53 binding site nor a TATA box, and Saos-
2 cells are known to be p53-negative cells (Masuda et PBP at all because of a five-nucleotide substitution at
the SphI site. pX58pM2CAT was also responsive to nor-al., 1987). Therefore, we carried out DNA transfection
experiments to Saos-2 cells using the Bal I/MboI DNA – mal p53 protein (data not shown). Thus, repression of
the X gene promoter activity by normal p53 protein ap-CAT construct (pX58pCAT) and its mutant pX58pM1CAT,
together with normal or mutant p53 expression plasmids pears to be closely correlated with the basal transcription
factor.(Table 1). When normal or mutant p53 gene and
pX58pCAT or pX58pM1CAT were cotransfected, normal To clarify the region of normal p53 protein responsible
for the repression of X gene promoter activity, severalp53 gene repressed CAT expression, while mutant p53
(p53 mutant DN or OM1) did not and, in contrast, slightly p53 mutants were examined. Consistent with the recent
observations by others (Shiio et al., 1992; Subler et al.,stimulated CAT expression for some unknown reason.
In other words, transfected normal p53 is able to repress 1992; Sang et al., 1994), any amino-terminal deletion
(DN) or carboxy-terminal deletion (345, 301, or 282) or aX gene promoter activity. Under the same conditions, the
creatine kinase gene promoter (pEtCAT) was activated point mutation at the central region (OM1) (Sakai and
Tsuchida, 1992) abolished the transcriptional repressionby transfected p53 gene (Table 1), consistent with the
previous data (Weintraub et al., 1991; Zambetti et al., function of the p53 protein (Fig. 4D).
We then prepared a nuclear extract from p53-negative1992).
Although there is no detailed information available yet Saos-2 cells to examine whether X-PBP migrates at a
different position in the mobility shift assay without p53on the kind of basal transcription factor involved in X
gene transcription, it was of interest to clarify whether protein. The Saos-2 cell extract showed the same X-PBP
band as that from HepG2 cells (Fig. 5A). In addition, anti-normal p53 protein regulates the 20-bp sequence for
promoter activity of the X gene. To examine the effect of p53 antibodies (PAb421 or PAb1801) did not supershift or
eliminate the X-PBP band (Fig. 5A). Data so far obtainedp53 protein on this minimal promoter sequence, different
amounts of the p53 expression plasmid and the constant indicate that the p53 protein is not a major constituent
of the X-PBP complex. Therefore, p53 binding to X-PBPamount of reporter plasmid pXMP2CAT containing the
20-bp sequence were cotransfected to HepG2 cells. As was tested using immunopurified normal p53 from the
baculovirus expression system and the HepG2 nuclearshown in Fig. 4A, activity of the X gene promoter was
clearly repressed by the transfected p53 gene in a dose- extract (NE) with or without anti-p53 antibody (PAb421)
or anti-SV40 T-Ag antibody (as a control). Any significantdependent manner. On the other hand, transcriptional
activation of the creatine kinase gene promoter was ob- interaction between X-PBP and normal p53 protein was
not detected under the conditions used (Fig. 5B). To con-served. More specifically, the same amount of p53 ex-
pression plasmid brought about more than 15-fold activa- firm that our p53 protein retains the sequence-specific
DNA binding activity, normal and mutant HOS(156Pro)tion in HepG2 cells (data not shown) or p53-negative
Saos-2 cells (Table 1 and Takada et al., 1994b). When p53 proteins were used with the consensus p53 binding
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FIG. 4. Repression of transcription from the X gene promoter by normal p53. (A) Dose-dependent repression of the X gene promoter activity
by normal p53. Various amounts of p53 expression plasmid, pCMVp53 (normal), were cotransfected with 10 mg of the X gene promoter – CAT
plasmid, pXMP2CAT, per 10-cm dish into HepG2 cells and CAT activity was assayed. The amounts of transfected p53 expression plasmid
are indicated at the bottom. Relative activity (RA) was calculated and is shown at the top. (B) Northern blot analysis of X mRNA from p53-
transfected or control cells. The X gene expression plasmid (pHBVX-1) or the HBV genomic plasmid (pHBV-dimer) in the quantity of 10 mg per
10-cm dish was transfected into HuH-7 cells with or without 2 mg per dish of p53 expression plasmid pCMVp53. Total RNAs were analyzed
using a 32P-labeled X gene probe. Later, the same filter was rehybridized with a 32P-labeled b-actin probe (WAKO Pure Chemical Industry
Ltd.) to confirm the amount of blotted RNAs. (C) Mutant X gene promoter at X-PBP binding site preserves response to p53. p53 expression
plasmid, pCMVp53 (normal), indicated as / or the control plasmid, pCMV, indicated as 0 (each 2 mg per 10-cm dish), was cotransfected with
10 mg per 10-cm dish of the X gene promoter CAT plasmid (pXMP2CAT) or 10 mg of the point mutant at the X-PBP binding site (pXMP2mCAT).
For structures of the reporter plasmids, see Fig. 1. Relative activity (RA) was calculated and is shown at the top. (D) Inability of mutant p53
to repress the transcription from the X gene promoter. Mutant p53 constructs were tested for their ability to repress transcription of the X
gene. Two micrograms per 10-cm dish of mutant p53 expression plasmid was transfected with the reporter plasmid pXMP2CAT (10 mg).
Transfected p53 expression plasmids were Vecter, pCMV; Wild, pCMVp53 (normal); 345, pCMVp53d(346-393); 301, pCMVp53d(302-393); 282,
pCMVp53d(283-393); OM1, pCMVOM1; and DN, pCMVp53DN. Data for the plasmid 301 were introduced from the separate experiment where
301 plasmid exhibited the same level of the activity as the control vector only.
DNA in the presence or absence of PAb421, which was the X gene promoter was found to be clearly activated
by X protein expression (Fig. 3), indicating that the X-reported to activate the sequence-specific DNA binding
responsive element is present in the X gene promoterof p53 (Hupp et al., 1992). As also shown in Fig. 5B, the
region. Because the X gene promoter activity was regu-small arrowhead to the right indicates the complex of
lated negatively by normal p53 protein or positively bynormal p53 protein and p53 binding DNA. The large ar-
X protein, CAT activity assay was then carried out torowhead to the right indicates the triple complex of
determine the effect of cotransfected X expression plas-PAb421, normal p53 protein, and p53 binding DNA.
mid on the transcriptional repression function of p53 pro-These observations strongly suggest that repression of
tein. As shown in Fig. 6, p53 repression of the X genethe X gene promoter activity by normal p53 protein is not
promoter activity (pXMP2CAT) was significantly recov-mediated through X-PBP.
ered by increasing the amount of cotransfected X gene.
This recovery depended on the Kunitz domain-like struc-X protein cancels the transcriptional repression by
ture of the X protein, which is essential for the transacti-transfected p53 gene
vation function of X protein (Takada et al., unpublished
As described above, when the CAT plasmid containing data). The data clearly indicated that the p53 transcrip-
wild-type or mutant X promoter was cotransfected with tional repression of X gene promoter activity can be coun-
the X gene expression plasmid (pHBVX-1) or the control teracted with X protein coexpression in the transient ex-
pression system using HepG2 cells. Normal endogenousplasmid (pBR322) into HepG2 cells, transcription from
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as the chromatin structure or by modification of the DNA
(Weintraub, 1985; Ptashne, 1988; Johson and McKnight,
1989). The amount of transcription factors in cells may
also affect the transcription activity (Rechesteiner, 1991).
A difference in responsiveness to X protein seems not
to be species-specific or simply tissue-specific (Seto et
al., 1989), so one can speculate that X protein has a
repertory of interaction partners, selects an appropriate
one among them according to the condition of the cell
or the concentration of factors in the cell, and transacti-
vates a specific set of genes in the cell in consequence.
Alternatively, X protein may catalytically modify a specific
set of transcription factors. Considering the previous ob-
servations, it is important to examine interaction between
X protein and cellular factors and/or the interaction part-
ner with X protein. Maguire et al. (1991) demonstrated
FIG. 5. Normal p53 protein was not detected in the X-PBP complex. that X protein could bind to CREB or ATF-2, making each
(A) Absence of normal p53 protein in the X-PBP complex. Left: A mobility bind tightly to a CRE-related sequence in the HBV en-
shift assay of X-PBP using 5 mg of protein of the nuclear extract from
hancer I. However, a direct interaction of X protein withSaos-2 (lane 1) or HepG2 (lane 2) cells. Right: A mobility shift assay
other XRE-binding proteins, such as NFkB or AP-1, hasof X-PBP using HepG2 nuclear extract in the absence (lane 3) or pres-
ence [100 ng (lanes 4 and 6) or 300 ng (lanes 5 and 7)] of anti-p53 not yet been published. In this context, Kekule et al.
antibodies. 32P-labeled M7 DNA was used as the probe. Arrowheads (1993) and Natoli et al. (1994b) detected increased AP-1
indicate the position of the X-PBP bands. (B) No direct interaction of binding to its specific binding DNA site in X protein-
X-PBP with normal p53 protein. A mobility shift assay was performed
expressing cells, but X protein was not detected in theusing 32P-labeled MP2 DNA (left, lanes 1–7) or p53 binding DNA (Hupp
DNA–protein (AP-1) complex. Therefore, further investi-et al., 1992) (right, lanes 8–11) as the probe. Poly(dA-dT)/poly(dA-dT)
was used as the nonspecific carrier. To see whether p53 protein binds gations are necessary to understand the exact role of X
to X-PBP, immunopurified normal p53 (50 ng) from the baculovirus protein in the increased binding of cellular factors to the
expression system was added to the HepG2 nuclear extract (NE), with X-responsive elements.
or without anti-p53 antibody (PAb421) or anti-SV40 T-Ag antibody (as
Previous observations indicated that X protein is ablea control). Arrowhead to the left indicates the simple X-PBP band from
to transcriptionally activate a number of upstream se-NE. Left: lane 1, NE alone; lane 2, NE and p53 protein; lane 3, NE, p53
protein and PAb421; lane 4, NE, p53 protein and anti-SV40 T-Ag; lane quences of viral and cellular genes. This is the first report
5, NE and mutant p53, HOS(156Pro); lane 6, p53 alone; lane 7, normal to demonstrate that X protein can activate the promoter
p53 and pAB421 together. To indicate that our p53 protein retains the activity without enhancer sequences. It is not clear why
sequence-specific DNA binding activity, normal (lanes 8 and 9) and
investigators previously did not point out the promotermutant HOS(156Pro) (lanes 10 and 11) p53 proteins were mixed with
activation function of X protein. Perhaps little attentionthe consensus p53 binding DNA in the presence (lane 9 and 11) or
absence (lanes 8 and 10) of PAb421. has been paid to the difference in promoter activity in
the presence or absence of X protein. In fact, we also
found that X protein activated the core promoter of the
p53 protein is probably one dominant determinant of the SV40 early gene (data not shown). Among the elements
occurrence of transcriptional activation by the X protein. for transcription initiation, the TATA box is the most com-
It is not certain whether there is a direct interaction be- mon sequence with which the transcription factor, TFIID,
tween p53 and X protein under the conditions used; how-
ever, X protein can up-regulate X gene transcription in
the presence of normal p53. This indication was sup-
ported by the fact that transactivation of the X gene as
well as cellular genes by the X protein can be observed
in several different cell lines expressing normal p53, but
not in its mutant cell lines (Takada et al., unpublished
data; see Discussion).
DISCUSSION
Promoter activation by X protein and the state of p53
FIG. 6. Disruption of transcriptional repression function of normal
protein p53 by X protein. Indicated amount (mg per 10-cm dish) of normal p53
and X expression plasmids (pCMVp53 and pHBVX-1, respectively) were
The activity of transcription is determined for each cotransfected to HepG2 cells and CAT activity assay was carried out
gene by transcriptional factors and their responsive ele- using 2 mg of pXMP2CAT as the reporter plasmid. Relative activity (RA)
was calculated and is shown at the top.ments in the regulatory DNA region of each gene as well
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interacts. Another initiation sequence, for instance, the standing the mechanism of X gene transcription. These
analyses are currently under investigation.GC box, is also known in a variety of genes. Since no
homology has been found between the X-PBP binding
Disruption of normal p53 function by X protein andsequence and the known initiation sequences, the se-
transactivationquence stretch including the X-PBP binding site may be
another type of initiator sequence. Although the physio- As we found that the X gene promoter activity was
logical function of X-PBP has not yet been fully character- negatively or positively regulated by p53 or X protein,
ized, the present data indicate that activation of the X respectively, the transcriptional activation function of X
gene promoter activity by X protein is unlikely to be medi- protein may be explained by the interference of normal
ated through X-PBP. p53 function with coexpressed X protein. Recently, sev-
It is known that activation by X protein is observed in eral studies have suggested that X protein influenced
different degrees according to the cell type (Seto et al., signal transduction pathways; for example, X protein
1989; Rossner, 1992). In this respect, it should be noted stimulated Ras–GTP complex formation and promoted
that some of the p53-defective cell lines, such as HuH- downstream signaling through Raf and MAP kinases
7 cells (Bressac et al., 1990), Cos cells (because of the (Benn and Schneider, 1994; Cross et al., 1993). It would
expression of SV40 T-Ag), and CV-1 cells, when be possible to speculate, therefore, that X protein influ-
transfected with SV40 T-Ag expression plasmid, exhib- ences one of the signal pathways, which may affect any
ited no transcriptional activation by X protein (Koike et al., of the cytosolic factors involved in the disruption of p53
1989; Spandau and Lee, 1988). The state of p53 protein is function.
probably one of the dominant determinants of cell type Binding of p53 to its DNA consensus sequence is nec-
specificity for occurrence of efficient transcriptional acti- essary for the transactivation of genes adjacent to these
vation by X protein. binding sites (Kern et al., 1991; Weintraub et al., 1991).
It has also been postulated that normal p53 modulates
gene transcription by interacting with the basic transcrip-Transcriptional repression of X gene promoter by p53
tional machinery, TFIID, a part of the transcription initia-protein
tion complex that has been shown to be a p53 target,
p53 was previously demonstrated to interact with the resulting in down-regulation of TFIID-dependent genes
TBP-associated factors TAFII40 and TAFII60 when acti- (Seto et al., 1992; Liu et al., 1993). HBV X protein seems
vating transcription through p53 binding DNA (Thut et al., to have such an effect on the p53 suppressor function,
1995) and the basal transcription factor TFIIH (Xiao et similar to that of oncogene products of other DNA tumor
al., 1994). Viral and cellular genes have been reported viruses, including SV40 T-antigen, human papilloma virus
to be negatively regulated by normal p53 (Deffie et al., E6, and adenovirus E1B. Viral replication may be trig-
1993; Shiio et al., 1992; Ginsberg et al., 1991; Santhanam gered through a disruption of the p53 suppressor func-
et al., 1991; Subler et al., 1992). It was also reported tion by X gene expression without any mutation of p53.
that normal p53 binds to TBP and inhibits transcriptional Recently, the in vitro interaction between p53 and X pro-
initiation by interfering with binding of the basal tran- teins was studied by fusing the entire X or normal and
scription factors to the TATA motif (Ragimov et al., 1993). mutant p53 ORFs to the GST (glutathione S-transferase)
In this study, we first determined the 20-bp region for X gene (Wang et al., 1994). Only the GST normal p53, but
gene promoter activity, which possesses none of the not GST mutant p53 or GST alone, bound the in vitro
typical promoter sequences and then examined whether translated X protein. These results are consistent with
normal p53 protein positively or negatively regulated X those of a previously reported study (Feitelson et al.,
gene transcription. We demonstrated that the promoter 1993). On the other hand, when the X gene expression
activity was repressed by normal p53 under the condi- plasmid was cotransfected with the p53 expression plas-
tions used. Although the requirement of TBP for transcrip- mid into HepG2 cells, we observed the major localization
tion from the X gene promoter is unknown because of of X protein in the cytoplasm (Takada et al., unpublished
the absence of the TATA motif, the mechanism of repres- data). Thereby, the repression function of p53 may be
sion of the X gene promoter may involve direct interfer- canceled by this cytoplasmic X protein by some unknown
ence of TBP function or TFIIH function with normal p53 mechanism in the cotransfected HepG2 cells. Further
protein. Normal p53 protein (synthesized and purified elucidation of the mechanism by which X protein, particu-
from the baculovirus expression system) exhibited no larly its serine protease inhibitor-like domain (Takada
sequence-specific binding activity to this 20-bp promoter and Koike, 1990a), disrupts the repressor function of p53
DNA under the conditions used (Figs. 5A and B). We also protein may prove to be fruitful in understanding the
observed that X-PBP binding correlated with the X gene pleiotropic effects of X protein.
promoter activity (Nakamura and Koike, 1992; this paper);
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